All Pfizer published press releases by date and/or category of news
10.12.2022 Vaccines COVID-19 Vaccines Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age 10.05.2022 Financial Investments Pfizer Completes Acquisition of Global Blood Therapeutics 10.04.2022 Research and Pipeline Research Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial 10.03.2022 Financial Finance Investments Pfizer Completes Acquisition of Biohaven Pharmaceuticals 09.26.2022 Vaccines Vaccines Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age 09.22.2022 Financial Finance Pfizer Declares Fourth-Quarter 2022 Dividend 09.22.2022 Prescription Medicines Medicines Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries 09.20.2022 Financial Finance Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts 09.19.2022 Research and Pipeline Research Vaccines Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union 09.15.2022 Vaccines Vaccines Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents 09.14.2022 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022 09.14.2022 Research and Pipeline Research Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
The latest news from Pfizer and its strategic partners
10.04.2022 Corporate Partnerships Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target 09.20.2022 Corporate Partnerships CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
United States, Canada and Latin America
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.